ErbB3 phosphorylation as central event in adaptive resistance to targeted therapy in metastatic melanoma: Early detection in CTCs during therapy and insights into regulation by autocrine neuregulin

Ciro Francesco Ruggiero, Debora Malpicci, Luigi Fattore, Gabriele Madonna, Vito Vanella, Domenico Mallardo, Domenico Liguoro, Valentina Salvati, Mariaelena Capone, Barbara Bedogni, Paolo Antonio Ascierto, Rita Mancini, Gennaro Ciliberto

Research output: Contribution to journalArticle

Abstract

In recent years the introduction of target therapies with BRAF and MEK inhibitors (MAPKi) and of immunotherapy with anti-CTLA-4 and anti-PD-1 monoclonal antibodies have dramatically improved survival of metastatic melanoma patients. Despite these changes drug resistance remains a major hurdle. Several mechanisms are at the basis of drug resistance. Particular attention has been devoted over the last years to unravel mechanisms at the basis of adaptive/non genetic resistance occurring in BRAF mutated melanomas upon treatment with to MAPKi. In this paper we focus on the involvement of activation of ErbB3 receptor following early exposure of melanoma cells to BRAF or MEK inhibitors, and the following induction of PI3K/AKT pathway. Although different mechanisms have been invoked in the past at the basis of this activation we show here with a combination of approaches that autocrine production of neuregulin by melanoma cells is a major factor responsible for ErbB3 phosphorylation and downstream AKT activation. Interestingly the kinetic of neuregulin production and of the ensuing ErbB3 phosphorylation is different in different melanoma cell lines which underscores the high degree of tumor heterogeneity. Moreover, heterogeneity is further highlighted by the evidence that in different cell lines neuregulin upregulation can occur at the transcriptional or at the post-transcritpional level. Finally we complement our study by showing with a liquid biopsy assay that circulating tumor cells (CTCs) from melanoma patients undergo upregulation of ErbB3 phosphorylation in vivo shortly after initiation of therapy.

Original languageEnglish (US)
Article number1425
JournalCancers
Volume11
Issue number10
DOIs
StatePublished - Oct 2019

Fingerprint

Neuregulins
Circulating Neoplastic Cells
Cell- and Tissue-Based Therapy
Melanoma
Phosphorylation
Mitogen-Activated Protein Kinase Kinases
Drug Resistance
Up-Regulation
Therapeutics
Cell Line
Phosphatidylinositol 3-Kinases
Immunotherapy
Monoclonal Antibodies
Biopsy
Survival

Keywords

  • Adaptive resistance
  • CTCs
  • ErbB3 phosphorylation
  • Melanoma
  • Neuregulin1
  • Target therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

ErbB3 phosphorylation as central event in adaptive resistance to targeted therapy in metastatic melanoma : Early detection in CTCs during therapy and insights into regulation by autocrine neuregulin. / Ruggiero, Ciro Francesco; Malpicci, Debora; Fattore, Luigi; Madonna, Gabriele; Vanella, Vito; Mallardo, Domenico; Liguoro, Domenico; Salvati, Valentina; Capone, Mariaelena; Bedogni, Barbara; Ascierto, Paolo Antonio; Mancini, Rita; Ciliberto, Gennaro.

In: Cancers, Vol. 11, No. 10, 1425, 10.2019.

Research output: Contribution to journalArticle

Ruggiero, CF, Malpicci, D, Fattore, L, Madonna, G, Vanella, V, Mallardo, D, Liguoro, D, Salvati, V, Capone, M, Bedogni, B, Ascierto, PA, Mancini, R & Ciliberto, G 2019, 'ErbB3 phosphorylation as central event in adaptive resistance to targeted therapy in metastatic melanoma: Early detection in CTCs during therapy and insights into regulation by autocrine neuregulin', Cancers, vol. 11, no. 10, 1425. https://doi.org/10.3390/cancers11101425
Ruggiero, Ciro Francesco ; Malpicci, Debora ; Fattore, Luigi ; Madonna, Gabriele ; Vanella, Vito ; Mallardo, Domenico ; Liguoro, Domenico ; Salvati, Valentina ; Capone, Mariaelena ; Bedogni, Barbara ; Ascierto, Paolo Antonio ; Mancini, Rita ; Ciliberto, Gennaro. / ErbB3 phosphorylation as central event in adaptive resistance to targeted therapy in metastatic melanoma : Early detection in CTCs during therapy and insights into regulation by autocrine neuregulin. In: Cancers. 2019 ; Vol. 11, No. 10.
@article{4026824afa2b4d3dace91dfac6ba9d25,
title = "ErbB3 phosphorylation as central event in adaptive resistance to targeted therapy in metastatic melanoma: Early detection in CTCs during therapy and insights into regulation by autocrine neuregulin",
abstract = "In recent years the introduction of target therapies with BRAF and MEK inhibitors (MAPKi) and of immunotherapy with anti-CTLA-4 and anti-PD-1 monoclonal antibodies have dramatically improved survival of metastatic melanoma patients. Despite these changes drug resistance remains a major hurdle. Several mechanisms are at the basis of drug resistance. Particular attention has been devoted over the last years to unravel mechanisms at the basis of adaptive/non genetic resistance occurring in BRAF mutated melanomas upon treatment with to MAPKi. In this paper we focus on the involvement of activation of ErbB3 receptor following early exposure of melanoma cells to BRAF or MEK inhibitors, and the following induction of PI3K/AKT pathway. Although different mechanisms have been invoked in the past at the basis of this activation we show here with a combination of approaches that autocrine production of neuregulin by melanoma cells is a major factor responsible for ErbB3 phosphorylation and downstream AKT activation. Interestingly the kinetic of neuregulin production and of the ensuing ErbB3 phosphorylation is different in different melanoma cell lines which underscores the high degree of tumor heterogeneity. Moreover, heterogeneity is further highlighted by the evidence that in different cell lines neuregulin upregulation can occur at the transcriptional or at the post-transcritpional level. Finally we complement our study by showing with a liquid biopsy assay that circulating tumor cells (CTCs) from melanoma patients undergo upregulation of ErbB3 phosphorylation in vivo shortly after initiation of therapy.",
keywords = "Adaptive resistance, CTCs, ErbB3 phosphorylation, Melanoma, Neuregulin1, Target therapy",
author = "Ruggiero, {Ciro Francesco} and Debora Malpicci and Luigi Fattore and Gabriele Madonna and Vito Vanella and Domenico Mallardo and Domenico Liguoro and Valentina Salvati and Mariaelena Capone and Barbara Bedogni and Ascierto, {Paolo Antonio} and Rita Mancini and Gennaro Ciliberto",
year = "2019",
month = "10",
doi = "10.3390/cancers11101425",
language = "English (US)",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "10",

}

TY - JOUR

T1 - ErbB3 phosphorylation as central event in adaptive resistance to targeted therapy in metastatic melanoma

T2 - Early detection in CTCs during therapy and insights into regulation by autocrine neuregulin

AU - Ruggiero, Ciro Francesco

AU - Malpicci, Debora

AU - Fattore, Luigi

AU - Madonna, Gabriele

AU - Vanella, Vito

AU - Mallardo, Domenico

AU - Liguoro, Domenico

AU - Salvati, Valentina

AU - Capone, Mariaelena

AU - Bedogni, Barbara

AU - Ascierto, Paolo Antonio

AU - Mancini, Rita

AU - Ciliberto, Gennaro

PY - 2019/10

Y1 - 2019/10

N2 - In recent years the introduction of target therapies with BRAF and MEK inhibitors (MAPKi) and of immunotherapy with anti-CTLA-4 and anti-PD-1 monoclonal antibodies have dramatically improved survival of metastatic melanoma patients. Despite these changes drug resistance remains a major hurdle. Several mechanisms are at the basis of drug resistance. Particular attention has been devoted over the last years to unravel mechanisms at the basis of adaptive/non genetic resistance occurring in BRAF mutated melanomas upon treatment with to MAPKi. In this paper we focus on the involvement of activation of ErbB3 receptor following early exposure of melanoma cells to BRAF or MEK inhibitors, and the following induction of PI3K/AKT pathway. Although different mechanisms have been invoked in the past at the basis of this activation we show here with a combination of approaches that autocrine production of neuregulin by melanoma cells is a major factor responsible for ErbB3 phosphorylation and downstream AKT activation. Interestingly the kinetic of neuregulin production and of the ensuing ErbB3 phosphorylation is different in different melanoma cell lines which underscores the high degree of tumor heterogeneity. Moreover, heterogeneity is further highlighted by the evidence that in different cell lines neuregulin upregulation can occur at the transcriptional or at the post-transcritpional level. Finally we complement our study by showing with a liquid biopsy assay that circulating tumor cells (CTCs) from melanoma patients undergo upregulation of ErbB3 phosphorylation in vivo shortly after initiation of therapy.

AB - In recent years the introduction of target therapies with BRAF and MEK inhibitors (MAPKi) and of immunotherapy with anti-CTLA-4 and anti-PD-1 monoclonal antibodies have dramatically improved survival of metastatic melanoma patients. Despite these changes drug resistance remains a major hurdle. Several mechanisms are at the basis of drug resistance. Particular attention has been devoted over the last years to unravel mechanisms at the basis of adaptive/non genetic resistance occurring in BRAF mutated melanomas upon treatment with to MAPKi. In this paper we focus on the involvement of activation of ErbB3 receptor following early exposure of melanoma cells to BRAF or MEK inhibitors, and the following induction of PI3K/AKT pathway. Although different mechanisms have been invoked in the past at the basis of this activation we show here with a combination of approaches that autocrine production of neuregulin by melanoma cells is a major factor responsible for ErbB3 phosphorylation and downstream AKT activation. Interestingly the kinetic of neuregulin production and of the ensuing ErbB3 phosphorylation is different in different melanoma cell lines which underscores the high degree of tumor heterogeneity. Moreover, heterogeneity is further highlighted by the evidence that in different cell lines neuregulin upregulation can occur at the transcriptional or at the post-transcritpional level. Finally we complement our study by showing with a liquid biopsy assay that circulating tumor cells (CTCs) from melanoma patients undergo upregulation of ErbB3 phosphorylation in vivo shortly after initiation of therapy.

KW - Adaptive resistance

KW - CTCs

KW - ErbB3 phosphorylation

KW - Melanoma

KW - Neuregulin1

KW - Target therapy

UR - http://www.scopus.com/inward/record.url?scp=85073435278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073435278&partnerID=8YFLogxK

U2 - 10.3390/cancers11101425

DO - 10.3390/cancers11101425

M3 - Article

AN - SCOPUS:85073435278

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 10

M1 - 1425

ER -